Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Page 6 of 23
Jul 22, 2026In a notable move, Novartis has discontinued development of a mid-stage radiopharmaceutical asset following unsatisfactory clinical data. This decision underscores the competitive dynamics of oncology R&D and highlights the shifting investment landscape as the company doubles down on its successful asset, Pluvicto.
Dr. Alex Morgan
Jul 21, 2026In a move set to reshape the peptide drug manufacturing landscape, Samsung Biologics has announced plans to acquire PolyPeptide for $1.8 billion. The acquisition is seen as a strategic response to surging demand for GLP-1 and similar obesity medications.
Daniel Cho
Jul 20, 2026Women’s oncology is on track to become a $110 billion market by 2030, highlighting vast opportunities for innovation and care improvement. However, a recent report spotlights persistent disparities in both funding and access, revealing the critical areas where stakeholders must focus to ensure growth benefits translate to better outcomes.
Michael Torres
Jul 18, 2026Physician burnout is reaching critical proportions, with broad implications for healthcare outcomes, institutional performance, and patient safety. A growing body of opinion now argues for dedicated measurement and intervention programs tailored to the unique stressors of different medical specialties.
Emily Carter
Jul 17, 2026GSK’s discontinuation of its cough program centered on Camlipixant signifies a cautionary tale about the risks and uncertainties facing large-cap pharmaceutical acquisitions. The outcome provides insight into how strategic bets in biopharma can shift course dramatically in the face of late-stage clinical trial setbacks.
Dr. Alex Morgan
Jul 17, 2026After recent events at the annual conference, the American Diabetes Association is experiencing continued upheaval. Leaders have reportedly intervened to prevent publication of pieces by editors at its flagship journal, underscoring deeper organizational challenges and raising questions about editorial independence and transparency.
Sophia Reynolds
Jul 16, 2026Braveheart Bio, Attovia Therapeutics, and Vogenx are entering the public markets with focused plans to challenge some of the dominant players in the pharmaceutical industry. Their IPO ambitions highlight not just a buoyant capital environment, but also sharpened competitive aims in cardiometabolic and immunology drug development.
Dr. Priya Nandakumar
Jul 16, 2026Following a recent Phase 3 failure, Pfizer has quietly discontinued a Seagen-developed antibody-drug conjugate (ADC) for solid tumors. This decision marks a significant moment for both Pfizer’s oncology ambitions and the broader ADC sector, known for high hopes and recurring setbacks.
Jonathan Blake
Jul 15, 2026Fairview Health Services’ journey from crippling deficit to financial stability has captured widespread attention within the healthcare finance community. This report offers a comprehensive, neutral analysis of Fairview’s leadership, organizational changes, and frontline-driven improvements based on the latest insights from their executive team.
Sophia Reynolds
Jul 14, 2026In a move reflecting the growing importance of the China-to-global innovation pipeline, AstraZeneca will pay $600 million upfront for worldwide rights to Zegfrovy, adding to its lung cancer portfolio and boosting Dizal’s international ambitions. This deal represents another significant step in cross-border biopharma partnerships as licensing agreements shape the future of oncology therapeutics.
Michael Torres
Jul 14, 2026The Q2 2026 Biopharma Job Market Report, released by BioSpace, provides a detailed overview of the current state of biopharma hiring. The report highlights rising job postings, a robust R&D hiring environment, and evolving trends that are shaping expectations for talent acquisition and company restructuring going forward.
Sophia Reynolds
Jul 13, 2026The recent workforce reductions at EMD Serono mark yet another sign of evolving economic pressures in the research-driven pharmaceutical industry. This development, closely tracked by industry watchers, highlights ongoing restructuring efforts and their multifaceted consequences across pharma pipelines, workforce stability, and long-term innovation.
Daniel ChoMachine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.